INTRODUCTION: In the central nervous system a disintegrin and metalloproteinase 10 (ADAM10) controls several functions such as neurodevelopment, synaptic plasticity and dendritic spine morphology thanks to its activity towards a high number of substrates, including the synaptic cell adhesion molecules as the Amyloid Precursor Protein, N-cadherin, Notch and Ephrins. In particular, ADAM10 plays a key role in the modulation of the molecular mechanisms responsible for dendritic spine formation, maturation and stabilization and in the regulation of the molecular organization of the glutamatergic synapse. Consequently, an alteration of ADAM10 activity is strictly correlated to the onset of different types of synaptopathies, ranging from neurodevelopmental disorders, i.e. autism spectrum disorders, to neurodegenerative diseases, i.e. Alzheimer's Disease. Areas covered: We describe the most recent discoveries in understanding of the role of ADAM10 activity at the glutamatergic excitatory synapse and its involvement in the onset of neurodevelopmental and neurodegenerative disorders. Expert opinion: A progress in the understanding of the molecular mechanisms driving ADAM10 activity at synapses and its alterations in brain disorders is the first step before designing a specific drug able to modulate ADAM10 activity.
ADAM10 as a therapeutic target for brain diseases : from developmental disorders to Alzheimer's disease / E. Marcello, B. Borroni, S. Pelucchi, F. Gardoni, M. Di Luca. - In: EXPERT OPINION ON THERAPEUTIC TARGETS. - ISSN 1472-8222. - 21:11(2017 Nov), pp. 1017-1026.
Titolo: | ADAM10 as a therapeutic target for brain diseases : from developmental disorders to Alzheimer's disease |
Autori: | GARDONI, FABRIZIO (Penultimo) DILUCA, MONICA MARIA GRAZIA (Ultimo) |
Parole Chiave: | autism spectrum disorders; neurodegeneration; synapse; trafficking; ADAM10 Protein; Alzheimer disease; Animals; autism spectrum disorder; brain diseases; drug design; humans; neurodegenerative diseases; neurodevelopmental disorders; neuronal plasticity; synapses; molecular targeted therapy; molecular medicine; pharmacology; drug discovery3003 pharmaceutical science; clinical biochemistrytry |
Settore Scientifico Disciplinare: | Settore BIO/14 - Farmacologia |
Progetto: | Meccanismi di patogenesi negli stadi precoci della malattia di Alzheimer: identificazione di target armacologici e biomarkers Development of innovative tools for Alzheimer Disease therapy Development of innovative tools for Alzheimer Disease therapy Validating ADAM10 as therapeutic target for dementia |
Data di pubblicazione: | nov-2017 |
Rivista: | |
Tipologia: | Article (author) |
Digital Object Identifier (DOI): | http://dx.doi.org/10.1080/14728222.2017.1386176 |
Appare nelle tipologie: | 01 - Articolo su periodico |
File in questo prodotto:
File | Descrizione | Tipologia | Licenza | |
---|---|---|---|---|
ExpOpinionn2017.pdf | Publisher's version/PDF | Administrator Richiedi una copia |